ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells $39,080.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of the business’s stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $78.16, for a total transaction of $39,080.00. Following the completion of the transaction, the vice president directly owned 78,390 shares of the company’s stock, valued at $6,126,962.40. This trade represents a 0.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

• On Monday, April 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $77.95, for a total transaction of $38,975.00.
• On Friday, March 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $72.62, for a total transaction of $36,310.00.

ANI Pharmaceuticals Stock Up 1.7%

ANIP traded up $1.38 during trading on Wednesday, hitting $80.88. The company had a trading volume of 308,836 shares, compared to its average volume of 412,504. The company has a market capitalization of $1.81 billion, a PE ratio of 20.48 and a beta of 0.46. ANI Pharmaceuticals, Inc. has a one year low of $56.71 and a one year high of $99.50. The firm’s 50-day moving average price is $77.08 and its 200 day moving average price is $80.70. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, beating the consensus estimate of $1.28 by $0.77. The business had revenue of $237.46 million for the quarter, compared to analysts’ expectations of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The firm’s revenue was up 20.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts expect that ANI Pharmaceuticals, Inc. will post 7.73 earnings per share for the current year.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in ANI Pharmaceuticals by 2.2% during the 4th quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock worth $103,022,000 after buying an additional 27,598 shares in the last quarter. State Street Corp lifted its position in ANI Pharmaceuticals by 2.2% during the 4th quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock worth $57,405,000 after buying an additional 15,496 shares in the last quarter. UBS Group AG lifted its position in ANI Pharmaceuticals by 45.8% during the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after buying an additional 185,172 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in ANI Pharmaceuticals by 8.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company’s stock worth $40,843,000 after buying an additional 43,523 shares in the last quarter. Finally, Tang Capital Management LLC lifted its position in ANI Pharmaceuticals by 51.6% during the 4th quarter. Tang Capital Management LLC now owns 481,437 shares of the specialty pharmaceutical company’s stock worth $38,005,000 after buying an additional 163,937 shares in the last quarter. 76.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ANIP. Guggenheim boosted their price objective on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Zacks Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 15th. Finally, Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $107.33.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.